7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Akari Therapeutics, Plc
(NASDAQ:AKTX) 

AKTX stock logo

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase I...

Full Time Employees: 10
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Akari Therapeutics Plc Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.32-2.85-2.37-1.9-1.42-0.95-0.470
Akari Therapeutics Plc Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.32-2.85-2.37-1.9-1.42-0.95-0.470
Akari Therapeutics Plc Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.040.090.130.180.220.270.31
Akari Therapeutics Plc (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -35.37-30.32-25.27-20.21-15.16-10.11-5.050
Akari Therapeutics Plc P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 019.6739.3559.0278.798.37118.04137.72
No extra charts and metrics for this ticker.